Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human immune cells.

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other hand ...

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got brighter. In an initial trial, a single dose of a CRISPR gene-editing therapy ...

Learn about Brink Therapeutics as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

Beam Therapeutics Inc.’s BEAM share price has surged by 5.12%, which has investors questioning if this is right time to sell.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

Learn more about whether Amarin Corporation plc or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor ...

However, sell-offs present great opportunities to buy stocks with significant upside potential. Further, CRISPR Therapeutics ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.